November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Earlier Indicator of Palbociclib Response Found for Patients with Breast Cancer
March 8th 2018According to findings published in<em> Nature Communications, </em>a blood test detecting early changes in circulating tumor DNA (ctDNA) may provide earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to the CDK4/6 inhibitor palbociclib (Ibrance).
Read More
A Look Back at FDA News in the Month of February
March 3rd 2018New indications were approved by the FDA within the last month, including abemaciclib for HER2-negative breast cancer, durvalumab for non–small cell lung cancer, and abiraterone acetate for castration-sensitive prostate cancer.
Read More
Liquid Biopsy Shows Potential for Predicting Survival Outcomes in TNBC
March 1st 2018According to results from a retrospective study published in the <em>Journal of Clinical Oncology, </em>low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.
Read More
Frontline Abemaciclib Granted FDA Approval for HR+/HER2- Breast Cancer
February 27th 2018Based on data from the phase III MONARCH 3 trial, abemaciclib has been granted FDA approval for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.
Read More
Significant Benefit of Adjuvant Chemo in ER-Negative, Locally Recurrent Breast Cancer Sustained
February 24th 2018In a final analysis of the phase III CALOR trial, the survival benefit demonstrated with adjuvant chemotherapy was sustained in patients with ER-negative breast cancer with isolated locoregional recurrence.
Read More
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer
February 15th 2018The optimal neoadjuvant chemotherapy regimen in triple-negative breast cancer has not been clearly defined. Achieving a pathologic complete response provides important prognostic information, and, especially in TNBC, is considered a surrogate endpoint for event-free survival.
Read More
Results of the CALGB 40502 Study in TNBC
February 14th 2018Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer, a randomized phase III trial of paclitaxel compared with nab-paclitaxel or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer.<br />
Watch
Off-the-Shelf Vaccine Investigated in Phase II Study of TNBC for Recurrence Prevention
February 13th 2018A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer TNBC.
Read More
Priyanka Sharma Named Vice Chair of SWOG Breast Committee
February 13th 2018Priyanka Sharma, MD, has been named vice chair of SWOG’s Breast Committee. Formerly known as the Southwest Oncology Group, SWOG is a global cancer research community and 1 of 5 National Cancer Institute (NCI) National Clinical Trials Network-funded groups.
Read More
Promising Findings for Alpelisib in Patients With PIK3CA-Altered Metastatic ER+/HER2- Breast Cancer
February 10th 2018Findings from a phase Ia, multicenter, open-label, study published in the <em>Journal of Clinical Oncology</em> showed a disease control rate of 58.2% with alpelisib (BYL719) in patients with advanced solid tumors.
Read More
Eflapegrastim (Rolontis), a novel long-acting granulocyte-colony stimulating factor, has met its primary endpoint of non-inferiority in duration of severe chemotherapy-induced neutropenia in comparison with pegfilgrastim (Neulasta) in the phase III ADVANCE study, according to Spectrum Pharmaceuticals, Inc., the biotechnology company developing the agent.
Read More
Patients With AR-Positive TNBC May Benefit From Enzalutamide Treatment
February 5th 2018In findings from the phase II MDV3100-11 study published in the<em> Journal of Clinical Oncology</em>, enzalutamide demonstrated early signs of efficacy in patients with androgen receptor-positive triple-negative breast cancer.
Read More
Kathy Albain Named First Huizenga Family Endowed Chair at Loyola University Chicago
January 24th 2018Kathy S. Albain, MD, has been named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Funded by Heidi Huizenga, one of Albain’s beholden patients, her husband, and her family, the endowed chair recognizes Albain’s notable contributions as a physician, research, teacher and mentor.
Read More
Taking on the Hospital/Community Practice Cost Differential
January 24th 2018Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.
Read More
Trastuzumab Does Not Increase Cardiac Toxicity in HER2+ Breast Cancer, Study Finds
January 18th 2018According to long-term follow-up results from the National Surgical Adjuvant Breast and Bowel Project B-31 trial published in the <em>Journal of Clinical Oncology</em>,<em> </em>trastuzumab (Herceptin) did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Read More
Rugo Discusses Long-Term Findings Supporting Nab-Paclitaxel as a Promising Option in First-Line TNBC
January 12th 2018Hope S. Rugo, MD, discusses findings of the CALGB 40502/NCCTG N063H study, which was a randomized phase III trial of paclitaxel compared with nab-paclitaxel or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer.
Read More
Expert Discusses Impressive Findings With Sacituzumab Govitecan in Metastatic TNBC
January 11th 2018Aditya Bardia, MD, MPH, discusses phase I/II trial of sacituzumab govitecan which showed favorable clinical activity in patients with relapsed or refractory metastatic triple-negative breast cancer who have received at least 2 prior treatment regimens.
Read More
Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC
January 10th 2018Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
Watch
Acupuncture Effective in Reducing AI-Associated Joint Pain in Women With Breast Cancer
January 9th 2018According to data from a randomized phase III trial presented at the 2017 San Antonio Breast Cancer Symposium, a mix of traditional and customized acupuncture techniques were effective in reducing pain and stiffness associated with aromatase inhibitor therapy in women with early-stage breast cancer.
Read More
Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer
January 9th 2018Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.
Watch
No Significant Efficacy Seen With Trastuzumab in HER2-Low Breast Cancer
January 9th 2018According to findings presented at the 2017 San Antonio Breast Cancer Symposium, no significant efficacy was seen in a trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein.
Read More